Trial Profile

A phase 1/2 clinical trial evaluating GLPG5301 in refractory/relapsed multiple myeloma (rrMM)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 30 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GLPG-5301 (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Acronyms PAPILIO-1
Sponsors Galapagos NV

Most Recent Events

23 Apr 2025 According to a Galapagos NV Media Release, patient enrollment in the Phase 1 part is progressing with topline results expected in 2026, which will guide Galapagos development strategy, Galapagos expects to present Phase 1 topline data at a future medical conference.
12 Feb 2025 Results presented in the Galapagos NV Media Release.
30 Oct 2024 According to a Galapagos NV Media Release, company resumed enrolment. hence, status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com